Effect of the antilipolytic nicotinic acid analogue acipimox on whole-body and skeletal muscle glucose metabolism in patients with non-insulin-dependent diabetes mellitus.
about
A novel antidiabetic drug, fasiglifam/TAK-875, acts as an ago-allosteric modulator of FFAR1Pathogenesis of insulin resistance in skeletal muscle.Mechanisms of insulin resistance after insulin-induced hypoglycemia in humans: the role of lipolysisDemonstration of a critical role for free fatty acids in mediating counterregulatory stimulation of gluconeogenesis and suppression of glucose utilization in humans.Internalization of the human nicotinic acid receptor GPR109A is regulated by G(i), GRK2, and arrestin3.Interaction between glucose and free fatty acid metabolism in human skeletal muscleUtilizing the second-meal effect in type 2 diabetes: practical use of a soya-yogurt snack.A systematic review of metabolite profiling in gestational diabetes mellitus.Hepatic glucose production: therapeutic target in type 2 diabetes?Inhibition of lipolysis in Type 2 diabetes normalizes glucose disposal without change in muscle glycogen synthesis rates.How free fatty acids inhibit glucose utilization in human skeletal muscle.A single session of low-intensity exercise is sufficient to enhance insulin sensitivity into the next day in obese adultsEffects of exercise training and diet on lipid kinetics during free fatty acid-induced insulin resistance in older obese humans with impaired glucose tolerance.Lipid metabolism in skeletal muscle: generation of adaptive and maladaptive intracellular signals for cellular function.Inhibition of adipose tissue lipolysis increases intramuscular lipid and glycogen use in vivo in humans.Nutrient effects: post-absorptive interactions.Pathogenesis of type 2 (non-insulin-dependent) diabetes mellitus: the role of skeletal muscle glucose uptake and hepatic glucose production in the development of hyperglycaemia. A critical comment.Decreased insulin activation of glycogen synthase in skeletal muscles in young nonobese Caucasian first-degree relatives of patients with non-insulin-dependent diabetes mellitus.The second-meal phenomenon in type 2 diabetesTissue differences in the response of the pyruvate dehydrogenase complex to a glucose load during the development of obesity in gold-thioglucose-obese mice.Effects of GH on urea, glucose and lipid metabolism, and insulin sensitivity during fasting in GH-deficient patients.Acipimox enhances spontaneous growth hormone secretion in obese women.Impact of short-term high-fat feeding on glucose and insulin metabolism in young healthy men.The second-meal phenomenon is associated with enhanced muscle glycogen storage in humans.Acute inhibition of lipolysis does not affect postprandial suppression of endogenous glucose production.Multiple defects of both hepatic and peripheral intracellular glucose processing contribute to the hyperglycaemia of NIDDM.Effects of blockade of fatty acid oxidation on whole body and tissue-specific glucose metabolism in rats.Targeting NAD+ in Metabolic Disease: New Insights Into an Old Molecule.Phosphorylation of Beta-3 adrenergic receptor at serine 247 by ERK MAP kinase drives lipolysis in obese adipocytes.
P2860
Q24338456-21B46CCB-0CD9-48FA-8EA7-AB8F5C44E834Q33812448-D8B563B7-9DF6-45E5-B3CB-B8035E039151Q33869737-A693DE07-7681-4ED0-8A0C-D9AA104E704AQ33903864-29C49018-68F6-42EB-B691-4694392EEE9BQ33991193-222B8AEE-E00A-4686-8309-2535BE177B1AQ34110324-E68688C2-98F2-4301-9219-EC8E13472116Q34351714-13F031B1-6B31-42C5-B028-67F825E7D51EQ34458995-77E10BCB-97A5-43AF-85A3-51CC6C63A9F1Q34722593-AF80A458-1555-4023-9F70-F804355A2825Q35215573-79602F0D-50FB-4FF1-9CB3-DAE6BE26EA56Q35773111-A4C38E67-7A23-4D87-9DD3-102CD74C307BQ37106384-7E95004A-35C3-460D-A62D-9D7544DEECB2Q37298090-9E1D257B-2BFB-4FB7-A0FB-D10AABA34611Q37970188-44D378ED-E64C-44C1-9A65-0ECF95BFABC1Q39367202-7836E235-3296-4AA3-BE1C-8D06D8E7FB24Q40417793-2B6B41C7-AFB9-49D2-A00B-0B558646885CQ40743226-E10680DA-1AFE-44C4-9FB6-9E78555C51A1Q41019246-84232162-EC9B-41D1-9694-93EB60E0020DQ41284608-2358E714-5903-432C-B4EE-2035175CEF75Q42019713-ABF9496D-9F6A-4D05-AE35-F8A67B799151Q44473624-AA60D8FC-6184-49D2-BDF8-36891D099E52Q44689975-603E82B2-C24E-489A-A6EE-A4571E84D387Q46068667-504CAF99-0B4A-4F84-9B59-842A079450B5Q46152290-528A4E31-05F0-41F3-AEA3-3F313A6F5831Q46584960-26B9D53A-B1E8-4C98-8233-95C22F6C9CC4Q51590381-6572C493-AE02-4705-A3FD-27C897AAFEC7Q51598909-5B8368DC-12B2-4B3E-8340-EF122ACA1027Q51776565-E70A735F-C350-4100-BBE3-5AF92259084CQ52718968-87B93275-C847-4C5A-894F-A323D2372B00
P2860
Effect of the antilipolytic nicotinic acid analogue acipimox on whole-body and skeletal muscle glucose metabolism in patients with non-insulin-dependent diabetes mellitus.
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
1991年论文
@zh
1991年论文
@zh-cn
name
Effect of the antilipolytic ni ...... n-dependent diabetes mellitus.
@en
type
label
Effect of the antilipolytic ni ...... n-dependent diabetes mellitus.
@en
prefLabel
Effect of the antilipolytic ni ...... n-dependent diabetes mellitus.
@en
P2093
P2860
P356
P1476
Effect of the antilipolytic ni ...... n-dependent diabetes mellitus.
@en
P2093
P2860
P304
P356
10.1172/JCI115432
P407
P577
1991-10-01T00:00:00Z